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BACKGROUND
Body-weight fluctuation is a risk factor for death and coronary events in patients 
without cardiovascular disease. It is not known whether variability in body weight 
affects outcomes in patients with coronary artery disease.
METHODS
We determined intraindividual f luctuations in body weight from baseline weight 
and follow-up visits and performed a post hoc analysis of the Treating to New 
Targets trial, which involved assessment of the efficacy and safety of lowering 
low-density lipoprotein cholesterol levels with atorvastatin. The primary outcome 
was any coronary event (a composite of death from coronary heart disease, non-
fatal myocardial infarction, resuscitated cardiac arrest, revascularization, or angina). 
Secondary outcomes were any cardiovascular event (a composite of any coronary 
event, a cerebrovascular event, peripheral vascular disease, or heart failure), death, 
myocardial infarction, or stroke.
RESULTS
Among 9509 participants, after adjustment for risk factors, baseline lipid levels, 
mean body weight, and weight change, each increase of 1 SD in body-weight vari-
ability (measured according to average successive variability and used as a time-
dependent covariate) was associated with an increase in the risk of any coronary 
event (2091 events; hazard ratio, 1.04; 95% confidence interval [CI], 1.01 to 1.07; 
P = 0.01), any cardiovascular event (2727 events; hazard ratio, 1.04; 95% CI, 1.02 to 
1.07; P <0.001), and death (487 events; hazard ratio, 1.09; 95% CI, 1.07 to 1.12; 
P<0.001). Among patients in the quintile with the highest variation in body weight, 
the risk of a coronary event was 64% higher, the risk of a cardiovascular event 85% 
higher, death 124% higher, myocardial infarction 117% higher, and stroke 136% 
higher than it was among those in the quintile with the lowest variation in body 
weight in adjusted models.
CONCLUSIONS
Among participants with coronary artery disease, fluctuation in body weight was 
associated with higher mortality and a higher rate of cardiovascular events indepen-
dent of traditional cardiovascular risk factors. (Funded by Pfizer; ClinicalTrials.gov 
number, NCT00327691.)
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Body-Weight Fluctuations in Coronary Disease
Obesity is an independent risk fac-tor for cardiovascular death and disease.1,2 Among participants in the Framingham 
Heart Study who were between 35 and 75 years 
of age and were followed for up to 44 years, 
overweight and obese participants were at a high-
er risk for the development of cardiovascular 
disease than participants of normal weight.3 
Weight gain is strongly associated with an in-
creased risk of death and disease among par-
ticipants without evident cardiovascular disease 
at baseline.4,5 Indeed, in obese persons, bariatric 
surgery followed by weight loss reduces the risk 
of cardiovascular disease, including hypertension, 
hypercholesterolemia, and diabetes.6-8 Although 
such findings hold in the general population, 
the relation between body weight and outcomes 
in patients with established cardiovascular dis-
ease is complex.9-14
Weight loss is commonly prescribed as a life-
style intervention in obese patients. However, 
weight loss is frequently followed by weight gain 
(or “weight cycling”) or by other patterns of weight 
f luctuation. Whether such fluctuations in body 
weight are associated with worse prognosis is 
controversial.15-18 We used data from the Treating 
to New Targets (TNT) trial, which involved pa-
tients with established coronary artery disease, 
in a post hoc analysis to explore the relation be-
tween intraindividual fluctuations in body weight 
and the risk of cardiovascular events.
Me thods
Study Design
We conducted a post hoc analysis of data from 
the TNT trial, a randomized trial involving 10,001 
patients with clinically evident coronary artery 
disease and levels of low-density lipoprotein (LDL) 
cholesterol below 130 mg per deciliter (3.4 mmol 
per liter) who had been randomly assigned to 
receive either 10 mg or 80 mg of atorvastatin per 
day. The design and the principal results have 
been described previously.19,20 The major criteria 
for exclusion are outlined in Table S1 in the Sup-
plementary Appendix, available with the full text 
of this article at NEJM.org. For our analysis, 
patients with at least two postbaseline measure-
ments of body weight were included.
Patients were followed at 3, 6, and 9 months, 
at 1 year, and every 6 months thereafter, at which 
times data on vital signs, including body weight, 
were collected. Patients were followed for a me-
dian of 4.9 years.20
The study was sponsored by Pfizer. The insti-
tutional review boards of participating centers 
approved the trial, and written informed consent 
was obtained from each patient. The first author 
designed the study, prepared the first draft of 
the manuscript, and decided to submit the manu-
script for publication. The lead statistician had 
full access to the data, analyzed the data, and 
vouches for the completeness, authenticity, in-
tegrity, and reliability of the data. None of the 
academic authors received any compensation for 
the work on this article.
Measures of Body-Weight Variability
Body-weight variability was defined as intraindi-
vidual variability in body weight between visits. 
Various measures of variability were used, includ-
ing average successive variability, which was de-
fined as the average absolute difference between 
successive values, standard deviation (SD), the 
coefficient of variation, and variability inde-
pendent of the mean, which was calculated as 
100 × SD ÷ meanbeta, where beta is the regression 
coefficient based on a natural logarithm of stan-
dard deviation on the natural logarithm of the 
mean. The uncorrected variability independent 
of the mean was corrected with the use of this 
formula: (variability independent of the uncorrect-
ed mean × mean of coefficient of variation) ÷ mean 
of variability independent of the uncorrected 
mean. Average successive variability was used as 
the primary variability measure.
Study Outcomes
The primary outcome was the occurrence of any 
coronary event (a composite of death from coro-
nary heart disease, nonfatal myocardial infarc-
tion, resuscitated cardiac arrest, revascularization, 
or angina).20 The secondary outcomes were any 
cardiovascular event (a composite of any coro-
nary event or cerebrovascular event, peripheral 
vascular disease, or heart failure) and individual 
end points of death, myocardial infarction, and 
stroke.20 In addition, new-onset diabetes was 
evaluated as an outcome.
Statistical Analysis
The relation between body-weight variability (as 
measured by average successive variability) and 
the risk of outcomes was evaluated with the use 
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of body-weight variability as both a continuous 
and a categorical variable. Any outcome reported 
before the visit at 3 months (the minimal time 
point at which to calculate body-weight variabil-
ity) was censored. The primary analyses evaluated 
body-weight variability as a time-dependent covari-
ate. Secondary analyses used non–time-dependent 
covariate models. To account for body-weight vari-
ability as a continuous variable, a Cox propor-
tional-hazards regression model was constructed, 
in which the variability measure was entered to 
calculate the hazard ratio for outcomes per in-
crease in variability of 1 SD. Four models were 
used, with model 1 being unadjusted; model 2 
adjusting model 1 for treatment effect (80 mg of 
atorvastatin vs. 10 mg of atorvastatin); model 3 
adjusting model 2 for mean body weight and 
change in weight, taking directionality into ac-
count (continuous variable); and model 4 adjusting 
model 3 for age, sex, race, diabetes, hyperten-
sion, and smoking status; chronic kidney disease 
and congestive heart failure; baseline levels of LDL 
cholesterol, total cholesterol, high-density lipo-
protein (HDL) cholesterol, and triglycerides; and 
time between initial and final weight measure-
ment (for non–time-dependent variable models).
For the treatment of body-weight variability as 
a categorical variable, patients were divided into 
quintiles of measures of body-weight variability. 
The rate of outcomes was evaluated for each of 
the quintiles. Cox proportional-hazards regres-
sion analysis (fitting the above four models) was 
performed to evaluate the risk of outcomes in the 
group in the highest quintile of body-weight vari-
ability versus the lowest quintile (reference hazard 
ratio, 1.0). Further analyses were performed to ex-
plore the relation between body-weight variability 
and outcomes on the basis of baseline body-
mass index (BMI; the weight in kilograms divided 
by the square of the height in meters). These 
analyses were performed to address the question 
of whether fluctuation in body weight is more 
harmful in an overweight or obese person than in 
a person of normal weight. Patients were assigned 
to one of three categories: normal weight (BMI, 
<25), overweight (BMI, 25 to <30), or obese (BMI, 
≥30). For each of these three groups, patients were 
further divided into two groups on the basis of 
high variability (greater than or equal to the me-
dian) or low variability (below the median). Un-
adjusted and adjusted models were constructed to 
evaluate the association of high variability in 
weight and the risk of the primary and second-
ary outcomes in each of the three BMI categories.
Sensitivity analyses were conducted as follows: 
first, by excluding patients with only two body-
weight measurements; second, by excluding pa-
tients with a history of heart failure; third, by 
calculating body-weight variability after exclud-
ing measurements in months 3 and 9 (in order to 
use evenly spaced measurements of body weight); 
fourth, by using other measures of variability 
(±SD, coefficient of variation, and variability in-
dependent of the mean) to evaluate the consis-
tency of the results; and fifth, by calculating 
body-weight variability over different cutoff 
points (18 months, 24 months, and 30 months) 
and evaluating the risk of the primary and sec-
ondary outcomes beyond those cutoff points.
All analyses were performed with the use of 
SAS Software, version 9.0 (SAS Institute). A P value 
of less than 0.05 (two-sided) was considered to 
indicate statistical significance. Given the explor-
atory nature of the analyses, no adjustment was 
made for multiple testing.
R esult s
Characteristics of the Patients
Among the 10,001 patients enrolled in the trial, 
9509 fulfilled the inclusion criteria for the present 
post hoc analysis. The mean baseline weight of 
the patients was 85±15 kg. The median time be-
tween the first and last measurements of weight 
was 4.7 years. The median number of weight 
measurements was 12 (range, 2 to 14) (Fig. S1A 
in the Supplementary Appendix). The median 
body-weight variability (as measured by average 
successive variability) was 1.76 kg (Fig. S1B in the 
Supplementary Appendix). The characteristics of 
patients with low body-weight variability (below 
the median) versus high body-weight variability 
(greater than or equal to the median) are outlined 
in Table 1.
Body-Weight Variability as a Continuous 
Variable and Outcomes
When body-wight variability was used as a time-
dependent covariate in the fully adjusted model 
(model 4), each increase in body-weight variabil-
ity of 1 SD (1.5 to 1.9 kg) increased the risk of any 
coronary event (2091 events; hazard ratio, 1.04; 
95% confidence interval [CI], 1.01 to 1.07; 
P = 0.01), any cardiovascular event (2727 events; 
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Characteristics
Low Body-Weight 
Variability 
 (N = 4754)
High Body-Weight 
Variability 
 (N = 4755)
Total 
(N = 9509) P Value
Age
Median — yr 63.4 60.4 61.8 <0.001
≥65 yr — no. (%) 2061 (43.4) 1550 (32.6) 3611 (38.0) <0.001
Male sex — no. (%) 3752 (78.9) 3955 (83.2) 7707 (81.0) <0.001
Race — no. (%)†
White 4462 (93.9) 4497 (94.6) 8959 (94.2) 0.001
Black 123 (2.6) 144 (3.0) 267 (2.8)
Asian  65 (1.4)  32 (0.7)  97 (1.0)
Other 104 (2.2)  82 (1.7) 186 (2.0)
Current smoker — no. (%)  523 (11.0)  722 (15.2) 1245 (13.1) <0.001
Weight — kg <0.001
Median 79.0 88.43 83.3
Range 38.5–166.5 44.1–170.1 38.5–170.1
Mean 79.4±12.6 90.1±16.1 84.7±15.4
Hypertension — no. (%) 2409 (50.7) 2714 (57.1) 5123 (53.9) <0.001
Diabetes mellitus — no. (%)  654 (13.8)  744 (15.6) 1398 (14.7) 0.01
Known cerebrovascular disease — no. (%) 204 (4.3) 267 (5.6) 471 (5.0) 0.003
Previous coronary-artery bypass grafting — no. (%) 2242 (47.2) 2190 (46.1) 4432 (46.6) 0.28
Previous percutaneous coronary intervention  
— no. (%)
2495 (52.5) 2620 (55.1) 5115 (53.8) 0.01
Known chronic heart failure — no. (%) 312 (6.6) 416 (8.7) 728 (7.7) <0.001
Chronic kidney disease — no. (%) 1588 (33.4) 1468 (30.9) 3056 (32.1) 0.01
Cholesterol at baseline — mg/dl
LDL 97.2±17.5 97.7±17.5 97.4±17.5 0.23
HDL 48.8±11.4 45.9±10.3 457.3±10.9 <0.001
Total 174.5±23.7 174.8±23.8 174.7±23.8 0.66
Triglycerides at baseline — mg/dl 143.5±67.8 157.3±72.5 150.4±70.5 <0.001
Systolic blood pressure <140 mm Hg — no. (%) 3134 (65.9) 3284 (69.1) 6418 (67.5) 0.001
Randomization according to treatment with atorvastatin  
— no. (%)
0.66
10 mg 2364 (49.7) 2386 (50.2) 4750 (50.0)
80 mg 2390 (50.3) 2369 (49.8) 4759 (50.0)
Outcomes — no. (%)
Any coronary event  884 (18.6) 1207 (25.4) 2091 (22.0) <0.001
Any cardiovascular event 1149 (24.2) 1578 (33.2) 2727 (28.7) <0.001
Death 185 (3.9) 302 (6.4) 487 (5.1) <0.001
Myocardial infarction — no. (%) 198 (4.2) 293 (6.2) 491 (5.2) <0.001
Stroke — no. (%) 101 (2.1) 145 (3.0) 246 (2.6) 0.004
New-onset diabetes — no./total no. (%) 222/3772 (5.9) 418/3633 (11.5) 640/7405 (8.6) <0.001
*  Plus–minus values are means ±SD. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. to convert the values 
for triglycerides to millimoles per liter, multiply by 0.01129. Low body-weight variability is variability below the median and high body-weight 
variability is variability above the median. Median average successive variability equals 1.76 kg. The total includes all participants studied. 
HDL denotes high-density lipoprotein, and LDL low-density lipoprotein.
†  Race was reported by participants.
Table 1. Characteristics of the Patients.*
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hazard ratio, 1.04; 95% CI, 1.02 to 1.07; P <0.001), 
and death (487 events; hazard ratio, 1.09; 95% CI, 
1.07 to 1.12; P<0.001), with a numerical increase 
in myocardial infarction (hazard ratio, 1.04; 95% 
CI, 0.98 to 1.09; P = 0.17) and stroke (hazard ra-
tio, 1.05; 95% CI, 0.97 to 1.13; P = 0.20) (Table 2, 
and Table S2A through S2F in the Supplemen-
tary Appendix). Furthermore, in the non–time-
dependent covariate model, each increase in body-
weight variability of 1 SD (1.62 kg) increased the 
risk of any coronary event (hazard ratio, 1.04; 
95% CI, 1.02 to 1.06; P <0.001), any cardiovascu-
lar event (hazard ratio, 1.04; 95% CI, 1.03 to 1.06; 
P<0.001), death (hazard ratio, 1.03; 95% CI, 1.01 
to 1.06; P = 0.01), myocardial infarction (hazard 
ratio, 1.04; 95% CI, 1.00 to 1.07; P = 0.04), and 
stroke (hazard ratio, 1.05; 95% CI, 1.00 to 1.09; 
P = 0.03) independent of traditional risk factors 
(Table S3 in the Supplementary Appendix). In ad-
dition, an increase in body-weight variability was 
associated with an increase in new-onset diabetes 
(hazard ratio, 1.08; 95% CI, 1.02 to 1.14; P = 0.009) 
(Table S3 in the Supplementary Appendix).
Quintiles of Body-Weight Variability  
and Outcomes
The rate of any coronary event, any cardiovascular 
event, death, myocardial infarction, stroke, and 
new-onset diabetes increased with each higher 
quintile of body-weight variability (Fig. 1, and 
Fig. S2A through S2D in the Supplementary Ap-
pendix). In the fully adjusted model (model 4), 
when compared with the lowest quintile, patients 
with the highest quintile of variability had an 
increase in the risk of any coronary event of 
64%, an increase in the risk of any cardiovascu-
lar event of 85%, an increase in the risk of death 
of 124%, an increase in the risk of myocardial 
infarction of 117%, an increase in the risk of 
stroke of 136%, and an increase in the risk of 
new-onset diabetes of 78% (Table 3), independent 
of traditional risk factors.
Baseline BMI, Body-Weight Variability,  
and Outcomes
In patients with normal body weight at baseline, 
high body-weight variability (greater than or equal 
to the median) was associated with a numerical 
increase in any coronary event as compared with 
low body-weight variability (less than the median), 
but this difference was not significant. However, 
among patients who were overweight or obese, T
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high variability in body weight was associated 
with a significantly higher risk of any coronary 
or cardiovascular event than among patients with 
low variability in body weight (Fig. 2A and 2B).
 Sensitivity Analysis
Sensitivity analyses that excluded patients with 
only two body-weight measurements, excluded 
patients with a history of heart failure, excluded 
months 3 and 9 in the calculation of variability, 
or used other measures of variability (SD, coeffi-
cient of variation, and variability independent of 
the mean) yielded largely similar results (Tables 
S4 through S9 in the Supplementary Appendix). 
In addition, sensitivity analyses that were com-
puted with measurement of variability in the first 
2 years and that were used to evaluate outcomes 
after 2 years showed largely similar results (Ta-
ble S10 in the Supplementary Appendix). More-
over, sensitivity analyses computed with measure-
ment of variability in the first 18 months and 
used to evaluate the primary outcome after 18 
months showed a consistent increase in the risk 
of any coronary event in both unadjusted models 
(hazard ratio, 1.05; 95% CI, 1.02 to 1.09; P = 0.002) 
and adjusted models (hazard ratio, 1.04; 95% CI, 
1.01 to 1.08; P = 0.03). Similar results were seen 
with a cutoff point of 30 months (unadjusted 
hazard ratio, 1.07; 95% CI, 1.03 to 1.11; P <0.001; 
adjusted hazard ratio, 1.06; 95% CI, 1.01 to 1.10; 
P = 0.009).
 Body Weight and Prognosis
In the primary analyses, mean body weight was 
a predictor of any coronary event, any cardiovas-
cular event, myocardial infarction, and new-onset 
diabetes independent of body-weight variability 
and treatment effect (Table S2A through S2F in 
the Supplementary Appendix). However, in the 
fully adjusted model, mean weight was a predic-
tor of new-onset diabetes but not of other out-
comes. Similarly, weight change (from baseline 
to final) was a predictor of new-onset diabetes 
but not of other outcomes. Figure S3 in the Sup-
plementary Appendix shows the example of a 
patient from the trial with high body-weight 
variability and worse prognosis.
 Discussion
In this post hoc analysis involving patients with 
established coronary artery disease who partici-
pated in the TNT trial, f luctuations in body 
weight were strongly associated with the risk of 
cardiovascular events and even death. Moreover, 
body-weight variability was associated with the 
risk of new-onset diabetes. The associations ob-
served were independent of the mean body weight 
and appeared to be independent of traditional 
risk factors.
In patients without cardiovascular disease, 
obesity is a major risk factor for insulin resis-
tance, diabetes, hypertension, dyslipidemia, heart 
Figure 1. Quintiles of Body-Weight Variability and Rates of Coronary 
and Cardiovascular Events.
A coronary event was defined as a composite of death from coronary heart 
disease, nonfatal myocardial infarction, resuscitated cardiac arrest, revas-
cularization, or angina. A cardiovascular event was defined as a composite 
of any coronary event or cerebrovascular event, peripheral vascular disease, 
or heart failure. ASV denotes average successive variability.
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failure, and coronary heart disease.2,21 In addi-
tion, weight gain is associated with an increased 
risk of illness and death.4,5 Dramatic weight loss, 
as seen after bariatric surgery, has been shown 
to produce clinically significant improvements 
related to the risk of cardiovascular disease, in-
cluding reductions in the risk of hypertension, 
hypercholesterolemia, and diabetes.6-8 As such, 
weight loss is an important lifestyle intervention.
However, in patients with established cardio-
vascular disease, an obesity paradox has been 
described in which some adverse findings occur 
less frequently among those who are overweight 
or obese than among those of normal weight. 
In an analysis of the International Verapamil 
SR-Trandolapril (INVEST) study, a trial involving 
22,576 patients with known coronary artery dis-
ease, mortality was 30% lower among overweight 
and obese patients, despite the fact that they had 
less effective blood-pressure control than a com-
parative group of patients of normal weight.9 
Similar findings have been described in patients 
with heart failure22,23 and those with coronary 
artery disease.11-13 The concept of an obesity para-
dox has been debated, and the findings that 
support it have been attributed to selection bias 
and confounding. Indeed, weight loss as a lifestyle 
intervention is recommended in obese patients, 
even for those with established cardiovascular 
disease.
Although weight loss is recommended, the 
usual pattern for most patients attempting inten-
tional weight loss is weight loss followed by 
weight gain. The question of whether such fluc-
tuation is detrimental to health is controversial. 
In an analysis from the Framingham Heart Study 
involving patients without known cardiovascular 
disease, highly variable body weights were as-
sociated with higher mortality and morbidity 
related to coronary heart disease.15,24 However, 
other cohort studies have failed to confirm these 
findings.16-18
Whether weight fluctuation affects prognosis 
in patients with coronary artery disease — for 
whom there is emphasis on lifestyle intervention 
— is not known. We reviewed data from more 
than 9000 patients with coronary artery disease 
Outcome
Adjusted Hazard Ratio 
(95% CI)* P Value
Any coronary event 1.64 (1.41–1.90) <0.001
Any cardiovascular event 1.85 (1.62–2.11) <0.001
Death 2.24 (1.74–2.89) <0.001
Myocardial infarction 2.17 (1.59–2.97) <0.001
Stroke 2.36 (1.56–3.58) <0.001
New-onset diabetes 1.78 (1.32–2.40) <0.001
*  Results were adjusted for age, sex, race, diabetes, hypertension, and smoking; 
mean weight and weight change (taking directionality into account); treat-
ment (80 mg of atorvastatin vs. 10 mg); baseline levels of LDL cholesterol, 
HDL cholesterol, total cholesterol, and triglycerides; chronic kidney disease 
and chronic heart failure; and time between initial and final weight measure-
ments.
Table 3. Multivariable Models and Risk of Outcomes in the Highest versus 
the Lowest Quintile of Variability in Body Weight.
Figure 2. Body-Weight Variability and Rates of Coronary 
and Cardiovascular Events as a Function of Baseline 
Body-Mass Index.
BMI denotes body-mass index (the weight in kilograms 
divided by the square of the height in meters), and 
BMV body-weight variability. Normal weight is defined 
as a BMI of less than 25, overweight a BMI of 25 to less 
than 30, and obesity a BMI of 30 or higher.
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and found that body-weight variability was as-
sociated with a significant increase in the risk 
of cardiovascular events and death. We also ob-
served a graded relation, such that greater de-
grees of body-weight fluctuation were associated 
with higher event rates. We also found that high 
versus low body-weight variability was associat-
ed with a greater absolute increase in the risk of 
any coronary event among overweight and obese 
persons than among persons of normal weight. 
Finally, our data indicate that body-weight vari-
ability was strongly and independently associated 
with new-onset diabetes mellitus.
The associations observed in our study may 
be due to reasons other than causality. Higher 
body-weight variability may be a marker of seri-
ous preexisting illnesses that have worse prog-
noses. However, our study used data from a ran-
domized trial that excluded patients with a poor 
prognosis. Moreover, the worse prognosis was 
also seen in cause-specific outcomes, such as 
coronary events, myocardial infarction, and stroke. 
Patients with systolic heart failure can have 
swings in body weight based on the status of 
their body-fluid volume. However, patients with 
New York Heart Association class IIIB and IV 
heart failure were excluded from the trial. Thus, 
volume changes would seem to be less likely to 
contribute to weight changes in our study. More-
over, our sensitivity analyses (excluding patients 
with a history of heart failure at baseline) yielded 
largely similar results. The fluctuations in body 
weight may be a consequence of — not the cause 
of — nonfatal end points. However, a sensitivity 
analysis in which we calculated body-weight 
variability at different cutoff points and evaluated 
outcomes beyond those cutoff points yielded 
largely similar results.
The present study has certain limitations. It 
tests association, not causation. Furthermore, the 
study did not assess whether the body-weight 
f luctuations were intentional or unintentional, 
factors that can have different effects on prog-
nosis.25 In addition, the study did not assess 
measures of obesity other than BMI. The sensi-
tivity analyses that assessed outcomes beyond a 
certain cutoff point were underpowered. Although 
the approach of calculating body-weight vari-
ability until a certain cutoff point and then 
evaluating its effects on events beyond that time 
frame offers a potential “causal” hypothesis, the 
disadvantage is that the body-weight variability 
calculated may not remain the same in the follow-
up phase, resulting in misclassification.
In this large cohort of patients with coronary 
artery disease, body-weight fluctuation was asso-
ciated with a significant increase in the risk of 
cardiovascular events and death. The magnitude 
of this risk increased with greater variability in 
body weight and among those who were over-
weight or obese at baseline and was indepen-
dent of traditional factors related to cardiovascu-
lar risk.
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